Anti-PD-1/PD-L1 inhibitor therapy for melanoma brain metastases: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Anti-PD-1/PD-L1 inhibitor therapy for melanoma brain metastases: a systematic review and meta-analysis

Published:2024-08-14 Issue:1 Volume:47 Page:
ISSN:1437-2320
Container-title:Neurosurgical Review
language:en
Short-container-title:Neurosurg Rev

Author:

Habibi Mohammad Amin^ORCID,Mirjani Mohammad Sina^ORCID,Ahmadvand Muhammad Hussain^ORCID,Delbari Pouria^ORCID,Eftekhar Mohammad Shahir,Ghazizadeh Yalda^ORCID,Ghezel Mohammad Amin^ORCID,Rad Romina Hamidi^ORCID,Vakili Kimia Ghazi^ORCID,Lotfi Sohrab^ORCID,Minaee Poriya,Eazi SeyedMohammad,Mehrizi Mohammad Ali Abouei,Ahmadpour Sajjad^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10143-024-02595-7.pdf

Reference50 articles.

1. van Not OJ et al (2023) A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors. Cancers (Basel) 15(11):2922

2. Milsch L, Gesierich A, Kreft S, Livingstone E, Zimmer L, Goebeler M et al (2018) Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade. Eur J Cancer 99:58–65

3. Vosoughi E, Lee JM, Miller JR, Nosrati M, Minor DR, Abendroth R et al (2018) Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. BMC Cancer 18(1):490

4. Gritsch D et al (2022) In Patients With Melanoma Brain Metastases, Is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic. Neurologist 27(5):290–297

5. Bocquet-Tremoureux S, Scharbarg E, Nguyen JM, Varey E, Quereux G, Saint-Jean M et al (2019) Efficacy and safety of nivolumab in metastatic melanoma: real-world practice. Eur J Dermatol 29(3):315–321